Anzeige
Mehr »
Lynx Broker
Login
Mittwoch, 16.10.2019 Börsentäglich über 12.000 News von 613 internationalen Medien
Konkurrenz beeindruckt! Bisher noch unentdeckt von Investoren ist die neue Technologie jetzt marktreif! Aktie vor Neubewertung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0BLFX ISIN: SE0001137985 Ticker-Symbol: BTPC 
Frankfurt
16.10.19
08:01 Uhr
0,213 Euro
-0,008
-3,63 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ACTIVE BIOTECH AB Chart 1 Jahr
5-Tage-Chart
ACTIVE BIOTECH AB 5-Tage-Chart
RealtimeGeldBriefZeit
0,227
0,249
13:36
19.11.2018 | 08:41
(22 Leser)
(0 Bewertungen)

PRESS RELEASE

In accordance with a decision made by the Annual General Meeting held on May 17, 2018, the Election Committee shall comprise the representatives for the three largest shareholders by votes, as per end of September 2018, and the Chairman of the Board.

For the 2019 Annual General Meeting, the Election Committee shall propose Board members and a Chairman of the Board, and fees to Board members and auditors. The following individuals were appointed representatives for the largest shareholders by votes and, accordingly, are members of the Election Committee:

Johnny Sommarlund, MGA Holding
Tomas Billing, Nordstjernan
Reza Khiabani, representing own holdings

Under the leadership of the Chairman of the Board, Mats Arnhög, the Election Committee shall prepare proposals to be presented to and decided upon at the Annual General Meeting on May 23, 2019.

Lund, November 19, 2018
Active Biotech AB (publ)

Helén Tuvesson
President and CEO

For further information, please contact:
Hans Kolam, CFO
Tel: +46 (0)46 19 20 44

Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company with focus on neurodegenerative/inflammatory diseases and cancer. Laquinimod, an orally administered small molecule with unique immunomodulatory properties in development for neurodegenerative diseases. ANYARA, an immunotherapy, in development for cancer indications in partnership with NeoTX Therapeutics Ltd. Furthermore, commercial activities are conducted for the tasquinimod, paquinimod and SILC projects. Please visit www.activebiotech.com (http://www.activebiotech.com) for more information.


Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46 19 20 00

This information was submitted for publication, through the agency of the contact person set out above, at 08.30 a.m. CET on November 19, 2018.

Active Biotech's election committee appointed (http://hugin.info/1002/R/2225861/873285.pdf)



This announcement is distributed by West Corporation on behalf of West Corporation clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Active Biotech via Globenewswire


© 2018 GlobeNewswire (Europe)